Literature DB >> 15214882

In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

C Cavusoglu1, Y Karaca-Derici, A Bilgic.   

Abstract

The relationship between resistance to rifampicin and rifabutin and genetic alterations in the rpoB gene of 41 rifampicin-resistant isolates of Mycobacterium tuberculosis was evaluated. Although 35 isolates with rifampicin MICs > or = 32 mg/L were also rifabutin-resistant, six isolates with rifampicin MICs of 2-16 mg/L were susceptible to rifabutin (MIC < or = 0.5 mg/L). Mutations Asp516Val, Asp516Tyr, Leu533Pro and the double mutation Met515Ile and Leu533Pro influenced susceptibility to rifampicin, but not to rifabutin. All mutations at codons 531 and 526, except one isolate with a His526Cys mutation, correlated with resistance to both compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15214882     DOI: 10.1111/j.1469-0691.2004.00917.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  33 in total

1.  The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Yanlin Zhao; Xingshan Cai; Chunming Luo; Cairong Zou; Xin Liu
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

3.  Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics.

Authors:  Ming Xu; Yan Ning Zhou; Beth P Goldstein; Ding Jun Jin
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

4.  Adaptation Through Lifestyle Switching Sculpts the Fitness Landscape of Evolving Populations: Implications for the Selection of Drug-Resistant Bacteria at Low Drug Pressures.

Authors:  Nishad Matange; Sushmitha Hegde; Swapnil Bodkhe
Journal:  Genetics       Date:  2019-01-22       Impact factor: 4.562

5.  Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples.

Authors:  Amanda C Brown; Josephine M Bryant; Katja Einer-Jensen; Jolyon Holdstock; Darren T Houniet; Jacqueline Z M Chan; Daniel P Depledge; Vladyslav Nikolayevskyy; Agnieszka Broda; Madeline J Stone; Mette T Christiansen; Rachel Williams; Michael B McAndrew; Helena Tutill; Julianne Brown; Mark Melzer; Caryn Rosmarin; Timothy D McHugh; Robert J Shorten; Francis Drobniewski; Graham Speight; Judith Breuer
Journal:  J Clin Microbiol       Date:  2015-05-13       Impact factor: 5.948

6.  Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis.

Authors:  Jimena Collantes; Francesca Barletta Solari; Leen Rigouts
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

7.  Characterization of Mutations Conferring Resistance to Rifampin in Mycobacterium tuberculosis Clinical Strains.

Authors:  Tomasz Jagielski; Zofia Bakuła; Anna Brzostek; Alina Minias; Radosław Stachowiak; Joanna Kalita; Agnieszka Napiórkowska; Ewa Augustynowicz-Kopeć; Anna Żaczek; Edita Vasiliauskiene; Jacek Bielecki; Jarosław Dziadek
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient.

Authors:  Francesca Meacci; Germano Orrù; Elisabetta Iona; Federico Giannoni; Claudio Piersimoni; Gianni Pozzi; Lanfranco Fattorini; Marco R Oggioni
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

9.  De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.

Authors:  Jees Sebastian; Sharmada Swaminath; Rashmi Ravindran Nair; Kishor Jakkala; Atul Pradhan; Parthasarathi Ajitkumar
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

10.  Direct observation therapy with appropriate treatment regimens was associated with a decline in second-line drug-resistant tuberculosis in Taiwan.

Authors:  J-Y Chien; C-C Tsou; S-T Chien; C-J Yu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.